報價延遲最少15分鐘:2025/07/02 00:52 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.67 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.08/-3.90
|
|
企業價值
249.19M
|
| 資產負債 |
|
每股賬面淨值
5.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
24.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/02 00:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |